15.05.2017 • News

GCP Applied Technologies Buys Stirling Lloyd

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

GCP Applied Technologies, a US provider of specialty chemicals and materials to the building and construction industries, has agreed to buy the UK’s Stirling Lloyd for $94 million.

With annual net sales of approximately $40 million, Stirling Lloyd supplies high-performance liquid waterproofing and coatings products for the protection of buildings and infrastructure.  Its headquarters and manufacturing facility are located in Manchester.

“This acquisition expands our technology platform for infrastructure and repair/renovation, market segments that are growing at attractive rates. Stirling Lloyd brings us complementary waterproofing systems; our global footprint will enable us to further increase penetration of these specialty products,” commented GCP’s president and CEO, Gregory Poling.

The transaction, which remains subject to local regulatory approvals, is expected to complete during the second quarter.

In March, the Cambridge, Massachusetts firm received a binding offer of about $1.05 billion from Germany’s Henkel to acquire the Darex Packaging Technologies business. When GCP was spun out of W.R. Grace in February 2016, the separation included the Darex business as well as the construction chemicals segment.

GCP said the sale of Darex, which is anticipated to close in the middle of 2017, would allow it to focus on growth opportunities in the construction and building materials market, while extending Henkel’s offering in the metal packaging industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read